NDRA Valuation

ENDRA Life Sciences Inc

Add to Watchlist

Advanced Chart

5.225

-0.675(-11.441%)1D

NDRA Relative Valuation

NDRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NDRA is overvalued; if below, it's undervalued.

Historical Valuation

ENDRA Life Sciences Inc (NDRA) is now in the Fair zone, suggesting that its current forward PS ratio of 5.90 is considered Fairly compared with the five-year average of -2.35. The fair price of ENDRA Life Sciences Inc (NDRA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：5.22

Fair

-0.69

Trailing

Forward

0.00

EV/EBITDA

ENDRA Life Sciences Inc. (NDRA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.56. The thresholds are as follows: Strongly Undervalued below -3.54, Undervalued between -3.54 and -2.05, Fairly Valued between 0.93 and -2.05, Overvalued between 0.93 and 2.42, and Strongly Overvalued above 2.42. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.37

EV/EBIT

ENDRA Life Sciences Inc. (NDRA) has a current EV/EBIT of -0.37. The 5-year average EV/EBIT is -1.43. The thresholds are as follows: Strongly Undervalued below -5.75, Undervalued between -5.75 and -3.59, Fairly Valued between 0.72 and -3.59, Overvalued between 0.72 and 2.88, and Strongly Overvalued above 2.88. The current Forward EV/EBIT of -0.37 falls within the Historic Trend Line -Fairly Valued range.

5.90

ENDRA Life Sciences Inc. (NDRA) has a current PS of 5.90. The 5-year average PS is 29.60. The thresholds are as follows: Strongly Undervalued below -112.40, Undervalued between -112.40 and -41.40, Fairly Valued between 100.59 and -41.40, Overvalued between 100.59 and 171.59, and Strongly Overvalued above 171.59. The current Forward PS of 5.90 falls within the Historic Trend Line -Fairly Valued range.

-0.64

P/OCF

ENDRA Life Sciences Inc. (NDRA) has a current P/OCF of -0.64. The 5-year average P/OCF is -2.99. The thresholds are as follows: Strongly Undervalued below -10.74, Undervalued between -10.74 and -6.86, Fairly Valued between 0.89 and -6.86, Overvalued between 0.89 and 4.77, and Strongly Overvalued above 4.77. The current Forward P/OCF of -0.64 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

ENDRA Life Sciences Inc. (NDRA) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.84. The thresholds are as follows: Strongly Undervalued below -5.78, Undervalued between -5.78 and -3.31, Fairly Valued between 1.63 and -3.31, Overvalued between 1.63 and 4.10, and Strongly Overvalued above 4.10. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

ENDRA Life Sciences Inc (NDRA) has a current Price-to-Book (P/B) ratio of 3.01. Compared to its 3-year average P/B ratio of 1.30 , the current P/B ratio is approximately 131.67% higher. Relative to its 5-year average P/B ratio of 2.44, the current P/B ratio is about 23.49% higher. ENDRA Life Sciences Inc (NDRA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -180.06%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -123.97% , the current FCF yield is about -100.00% lower.

3.01

P/B

Median3y

1.30

Median5y

2.44

0.00

FCF Yield

Median3y

-180.06

Median5y

-123.97

Competitors Valuation Multiple

The average P/S ratio for NDRA's competitors is 3.56, providing a benchmark for relative valuation. ENDRA Life Sciences Inc Corp (NDRA) exhibits a P/S ratio of 5.90, which is 65.95% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NDRA.O

ENDRA Life Sciences Inc

Autonomix Medical Inc

Cardio Diagnostics Holdings Inc

Meihua International Medical Technologies Co Ltd

0.23

7.20M

Performance Decomposition

Market capitalization of NDRA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NDRA in the past 1 year is driven by Unknown.